SSY GROUP(02005),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02005 SSY GROUP

Closed 12-22 16:08:10

2.930

-0.030

-1.01%

High2.970	Low2.910	Vol3.67M
Open2.940	D1 Closing2.960	Amplitude2.03%
Mkt Cap8.51B	Tradable Cap8.51B	Total Shares2.91B
T/O10.75M	T/O Rate0.13%	Tradable Shares2.91B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"SSY GROUP","latestPrice":2.93,"timestamp":1766390890005,"preClose":2.96,"halted":0,"volume":3668000,"delay":0,"floatShares":2905000000,"shares":2905000000,"eps":0.358192,"marketStatus":"Closed","change":-0.03,"latestTime":"12-22 16:08:10","open":2.94,"high":2.97,"low":2.91,"amount":10748520,"amplitude":0.02027,"askPrice":2.93,"askSize":74000,"bidPrice":2.92,"bidSize":102000,"shortable":3,"etf":0,"ttmEps":0.223096,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766453400000},"marketStatusCode":5,"adr":0,"listingDate":1135008000000,"exchange":"SEHK","adjPreClose":2.96,"dividendRate":0.049488,"openAndCloseTimeList":[[1766367000000,1766376000000],[1766379600000,1766390400000]],"volumeRatio":0.678884,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005","defaultTab":"news","newsList":[{"id":"2593129535","title":"New NMPA Drug Approvals Might Change The Case For Investing In SSY Group (SEHK:2005)","url":"https://stock-news.laohu8.com/highlight/detail?id=2593129535","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593129535?lang=en_us&edition=fundamental","pubTime":"2025-12-21 13:15","pubTimestamp":1766294153,"startTime":"0","endTime":"0","summary":"Earlier in December 2025, SSY Group announced that it had received NMPA approval in China to produce and register Levofloxacin Eye Drops and Compound Sodium Picosulfate Granules, both classified as having passed consistency evaluation.\nThese approvals deepen SSY Group’s ophthalmic and gastrointestinal product lineup, potentially strengthening its position in specialist hospital and pre-procedure medication markets.\nWe’ll now examine how the NMPA approvals, particularly the Levofloxacin Eye...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/new-nmpa-drug-approvals-might-change-the-case-for-investing","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/new-nmpa-drug-approvals-might-change-the-case-for-investing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","SSY","BK4185","02005","LU2460026573.USD"],"gpt_icon":0},{"id":"2592119941","title":"SSY Group (SEHK:2005): Valuation Check After New China Drug Approvals Expand Commercial Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2592119941","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592119941?lang=en_us&edition=fundamental","pubTime":"2025-12-20 08:29","pubTimestamp":1766190551,"startTime":"0","endTime":"0","summary":"SSY Group (SEHK:2005) just cleared an important regulatory hurdle in China, securing NMPA approvals for its Levofloxacin Eye Drops and Compound Sodium Picosulfate Granules, both passing consistency evaluations that support broader commercialization.\nSee our latest analysis for SSY Group.\nDespite the positive news, SSY Group’s HK$2.96 share price still reflects a muted mood, with a negative year to date share price return and a three year total shareholder return that suggests sentiment has...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/ssy-group-sehk2005-valuation-check-after-new-china-drug-appr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/ssy-group-sehk2005-valuation-check-after-new-china-drug-appr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","DCF","SSY","BK4185","LU2460026573.USD","02005"],"gpt_icon":0},{"id":"1185372335","title":"SSY GROUP (02005) Obtains Drug Production Registration Approval for Acetylcysteine Injection (25ml: 5g)","url":"https://stock-news.laohu8.com/highlight/detail?id=1185372335","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185372335?lang=en_us&edition=fundamental","pubTime":"2025-12-11 16:40","pubTimestamp":1765442419,"startTime":"0","endTime":"0","summary":"SSY GROUP (02005) announced that the company has obtained the drug production registration approval from China's National Medical Products Administration for Acetylcysteine Injection (25ml: 5g)....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2460026573.USD","02005","BK1191"],"gpt_icon":0},{"id":"2590595665","title":"SSY Group Wins NMPA Approval for Acetylcysteine and Compound Sodium Acetate Ringer's Injections","url":"https://stock-news.laohu8.com/highlight/detail?id=2590595665","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590595665?lang=en_us&edition=fundamental","pubTime":"2025-12-11 16:32","pubTimestamp":1765441955,"startTime":"0","endTime":"0","summary":"SSY Group Ltd. has announced that it has received approval from the National Medical Products Administration of China  for the production and registration of two pharmaceutical products. The approvals cover Acetylcysteine Injection , used for the detoxification of acute acetaminophen poisoning, and Compound Sodium Acetate Ringer's Injection , used for supplementing extracellular fluid and correcting metabolic acidosis. Both products are classified as type 3 chemical drugs and have passed the required consistency evaluation. No other organizations were mentioned as recipients of these approvals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the Issu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLc6ldyQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD"],"gpt_icon":0},{"id":"2590595636","title":"SSY Group - Obtains Approval for Acetylcysteine Injection From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2590595636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590595636?lang=en_us&edition=fundamental","pubTime":"2025-12-11 16:31","pubTimestamp":1765441910,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2460026573.USD","BK1191","02005"],"gpt_icon":0},{"id":"2590793392","title":"BRIEF-SSY Group Obtains Approval From China's NMPA For Levofloxacin Eye Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2590793392","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590793392?lang=en_us&edition=fundamental","pubTime":"2025-12-09 14:02","pubTimestamp":1765260179,"startTime":"0","endTime":"0","summary":"BRIEF-SSY Group Obtains Approval From China's NMPA For Levofloxacin Eye DropsDec 9  - SSY Group Ltd 2005.HK:OBTAINS APPROVAL FROM CHINA'S NMPA FOR LEVOFLOXACIN EYE DROPSOBTAINS APPROVAL FOR COMPOUND SODIUM PICOSULFATE GRANULES FROM NMPAFurther company coverage: 2005.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02005","LU2460026573.USD"],"gpt_icon":0},{"id":"2590394131","title":"SSY Group Gets China Nod for Registration of Two Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2590394131","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590394131?lang=en_us&edition=fundamental","pubTime":"2025-12-09 13:12","pubTimestamp":1765257172,"startTime":"0","endTime":"0","summary":"SSY Group  obtained production and registration approval for two products from China's National Medical Products Administration, a Tuesday Hong Kong bourse filing said.The approvals are for Levofloxacin Eye Drops used to treat blepharitis, meibomianitis, dacryocystitis, and conjunctivitis among other illnesses, and Compound Sodium Picosulfate Granules used in bowel cleansing preparation before colonoscopy, X-ray, and surgery.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02005","BK1191","BK4185","SSY","LU2460026573.USD"],"gpt_icon":0},{"id":"1199237483","title":"SSY GROUP (02005) Obtains NMPA Approval for Levofloxacin Eye Drops Production","url":"https://stock-news.laohu8.com/highlight/detail?id=1199237483","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199237483?lang=en_us&edition=fundamental","pubTime":"2025-12-09 12:12","pubTimestamp":1765253537,"startTime":"0","endTime":"0","summary":"SSY GROUP (02005) announced that it has obtained the drug production registration approval from China's National Medical Products Administration (NMPA) for Levofloxacin Eye Drops (0.488% (5ml:...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02005","LU2460026573.USD"],"gpt_icon":0},{"id":"2590439905","title":"SSY Group - Obtains Approval for Compound Sodium Picosulfate Granules From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2590439905","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590439905?lang=en_us&edition=fundamental","pubTime":"2025-12-09 12:01","pubTimestamp":1765252915,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1HP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02005","BK1191","LU2460026573.USD"],"gpt_icon":0},{"id":"2589860157","title":"BRIEF-Ssy Group Says Finerenone Has Obtained Approval For Registration From NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2589860157","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589860157?lang=en_us&edition=fundamental","pubTime":"2025-12-05 16:55","pubTimestamp":1764924940,"startTime":"0","endTime":"0","summary":"BRIEF-Ssy Group Says Finerenone Has Obtained Approval For Registration From NMPADec 5 (Reuters) - SSY Group Ltd 2005.HK:FINERENONE HAS OBTAINED APPROVAL FOR REGISTRATION FROM NMPAFurther company coverage: 2005.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XA17K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","LU2460026573.USD","BK1191"],"gpt_icon":0},{"id":"2589867105","title":"SSY Group Secures China Approval for Finerenone Bulk Drug Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2589867105","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589867105?lang=en_us&edition=fundamental","pubTime":"2025-12-05 16:32","pubTimestamp":1764923550,"startTime":"0","endTime":"0","summary":"SSY Group Ltd. has announced that its Finerenone product has received registration approval from the National Medical Products Administration of China as a bulk drug for preparations on the market. This marks the second such approval for entities in the People's Republic of China. Finerenone is primarily used in adult patients with chronic kidney disease associated with type 2 diabetes, helping to reduce risks of sustained decline in kidney function, end-stage renal disease, cardiovascular death, and hospitalization due to heart failure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8g6RzV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2460026573.USD","BK1191","02005"],"gpt_icon":0},{"id":"2589386710","title":"SSY Group - Finerenone Has Obtained Approval for Registration From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2589386710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589386710?lang=en_us&edition=fundamental","pubTime":"2025-12-05 16:32","pubTimestamp":1764923534,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XA17K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","LU2460026573.USD","02005"],"gpt_icon":0},{"id":"2589289361","title":"Is NMPA’s Wave Of Drug Approvals Altering The Investment Case For SSY Group (SEHK:2005)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589289361","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589289361?lang=en_us&edition=fundamental","pubTime":"2025-12-05 14:15","pubTimestamp":1764915301,"startTime":"0","endTime":"0","summary":"In late November 2025, SSY Group reported a series of approvals from China’s National Medical Products Administration for new and existing drugs, including treatments for overactive bladder, respiratory diseases, liver-related cholestasis and vitamin A supplementation.\nThese clustered approvals, many classified as passing China’s consistency evaluation, underline SSY Group’s push to broaden its portfolio of higher-quality, regulated pharmaceutical products in its home market.\nWe’ll examine...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/is-nmpas-wave-of-drug-approvals-altering-the-investment-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/is-nmpas-wave-of-drug-approvals-altering-the-investment-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SSY","LU2460026573.USD","BK4185","02005","BK1191"],"gpt_icon":0},{"id":"2588000809","title":"SSY Group Gets Bulk Drug Approvals in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2588000809","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588000809?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:36","pubTimestamp":1764840995,"startTime":"0","endTime":"0","summary":"SSY Group  obtained registration approvals for Bilastine and Sodium Picosulfate from China's National Medical Products Administration to become bulk drugs for preparations on the market, a Thursday Hong Kong bourse filing said.Bilastine is mainly used for the symptomatic treatment of urticaria, while sodium picosulfate is used to cleanse the colon before surgical examination.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02005","LU2460026573.USD","SSY","BK1191","BK4185"],"gpt_icon":0},{"id":"1116439160","title":"SSY GROUP (02005): Bilastine and Sodium Picosulfate Approved by NMPA as Active Pharmaceutical Ingredients for Marketed Preparations","url":"https://stock-news.laohu8.com/highlight/detail?id=1116439160","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116439160?lang=en_us&edition=fundamental","pubTime":"2025-12-04 16:36","pubTimestamp":1764837386,"startTime":"0","endTime":"0","summary":"SSY GROUP (02005) announced that its Bilastine and Sodium Picosulfate have been approved by China's National Medical Products Administration (NMPA) for registration as active pharmaceutical...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD"],"gpt_icon":0},{"id":"2588677004","title":"BRIEF-Ssy Group Says Bilastine And Sodium Picosulfate Approved In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2588677004","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588677004?lang=en_us&edition=fundamental","pubTime":"2025-12-04 16:32","pubTimestamp":1764837170,"startTime":"0","endTime":"0","summary":"BRIEF-Ssy Group Says Bilastine And Sodium Picosulfate Approved In ChinaDec 4 (Reuters) - SSY Group Ltd 2005.HK:BILASTINE AND SODIUM PICOSULFATE APPROVED IN CHINAFurther company coverage: 2005.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0BD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD"],"gpt_icon":0},{"id":"2588046780","title":"SSY Group - Bilastine and Sodium Picosulfate Approved in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046780?lang=en_us&edition=fundamental","pubTime":"2025-12-04 16:31","pubTimestamp":1764837097,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0BD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02005","BK1191","LU2460026573.USD"],"gpt_icon":0},{"id":"2588704897","title":"Assessing SSY Group (SEHK:2005) Valuation Following New Drug Approvals and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2588704897","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588704897?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:16","pubTimestamp":1764609400,"startTime":"0","endTime":"0","summary":"SSY Group (SEHK:2005) just secured multiple new drug production and registration approvals from China’s National Medical Products Administration, spanning both specialty treatments and bulk drugs. This signals tangible advancement in the company’s pharmaceutical pipeline.\nSee our latest analysis for SSY Group.\nAfter a challenging start to the year, SSY Group’s share price has shown renewed momentum, achieving a 9.5% return over the past 90 days and rising 1.6% just yesterday as investors...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/assessing-ssy-group-sehk2005-valuation-following-new-drug-ap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/assessing-ssy-group-sehk2005-valuation-following-new-drug-ap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4097","02005","LU2065732104.USD","DCF","LU2460026573.USD","PRGS","SSY","BK1191","BK4185"],"gpt_icon":0},{"id":"1143523099","title":"SSY Group Limited (02005) Announces November 2025 Share Capital Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1143523099","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143523099?lang=en_us&edition=fundamental","pubTime":"2025-12-01 17:06","pubTimestamp":1764579996,"startTime":"0","endTime":"0","summary":"SSY Group Limited disclosed that it maintained its total authorized share capital at HKD 200,000,000 for November 2025, represented by 10,000,000,000 ordinary shares at a par value of HKD 0.02 each....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"gpt_icon":0},{"id":"1172667579","title":"HKEX Shareholder Rights Disclosures on December 1","url":"https://stock-news.laohu8.com/highlight/detail?id=1172667579","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172667579?lang=en_us&edition=fundamental","pubTime":"2025-12-01 08:06","pubTimestamp":1764547574,"startTime":"0","endTime":"0","summary":"Latest shareholder rights disclosures were made on December 1, 2025, for FAST RETAIL-DRS (06288), SSY GROUP (02005), and LFG INV HLDGS (03938). For FAST RETAIL-DRS (06288), Yanai Tadashi's long...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","03938","IE00B66KJ199.SGD","IE00B7SZL793.SGD","IE00BFXG0V08.USD","BK1147","06288","DRS","BK1114","BK4187","FAST","BK4585","IE00B5TLWC47.USD","02005","IE00B19Z4B17.USD","BK4104","BK1191","BK4588","IE00BYQQ9H92.USD","BK1502","IE0031619046.USD","LU2460026573.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0},{"period":"6month","weight":0.1103},{"period":"1year","weight":-0.0579},{"period":"ytd","weight":-0.1292}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.006433},{"month":2,"riseRate":0.55,"avgChangeRate":0.025906},{"month":3,"riseRate":0.7,"avgChangeRate":0.087461},{"month":4,"riseRate":0.5,"avgChangeRate":0.035812},{"month":5,"riseRate":0.45,"avgChangeRate":0.00985},{"month":6,"riseRate":0.5,"avgChangeRate":0.067908},{"month":7,"riseRate":0.35,"avgChangeRate":-0.027819},{"month":8,"riseRate":0.35,"avgChangeRate":-0.017769},{"month":9,"riseRate":0.3,"avgChangeRate":-0.04678},{"month":10,"riseRate":0.45,"avgChangeRate":-0.001982},{"month":11,"riseRate":0.65,"avgChangeRate":0.086372},{"month":12,"riseRate":0.5,"avgChangeRate":-0.007052}],"exchange":"SEHK","name":"SSY GROUP","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SSY GROUP(02005),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SSY GROUP(02005) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SSY GROUP,02005,SSY GROUP股票,SSY GROUP股票老虎,SSY GROUP股票老虎国际,SSY GROUP行情,SSY GROUP股票行情,SSY GROUP股价,SSY GROUP股市,SSY GROUP股票价格,SSY GROUP股票交易,SSY GROUP股票购买,SSY GROUP股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SSY GROUP(02005),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SSY GROUP(02005) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}